CTOs on the Move

NCG Medical Systems

www.ncgmedical.com

 
NCG Medical Systems is a Altamonte Springs, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.ncgmedical.com
  • 140 N Westmonte Dr Ste 100
    Altamonte Springs, FL USA 32714
  • Phone: 407.788.1906

Executives

Name Title Contact Details

Similar Companies

Kaken Pharmaceuticals

Kaken Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Talis Biomedical

Talis is developing a new class of diagnostic platform to enable rapid, high-complexity testing across a wide range of healthcare settings.

clarient

clarient is a Aliso Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mana Therapeutics

MANA was founded in November 2018, based on the research and human proof-of-concept clinical trials conducted by Dr. Catherine Bollard and her team at Children`s National Hospital (CNH) in Washington, D.C., along with colleagues at Johns Hopkins Medical Center.

Werewolf Therapeutics

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body`s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.